PD 360324

Drug Profile

PD 360324

Alternative Names: PD-0360324; PD-360,324

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Cutaneous lupus erythematosus; Pulmonary sarcoidosis; Rheumatoid arthritis

Most Recent Events

  • 06 Nov 2014 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA, Canada & Moldova (IV)
  • 06 Nov 2014 Discontinued - Phase-II for Pulmonary sarcoidosis in USA (IV)
  • 24 Mar 2014 Pfizer terminates phase II trial in Pulmonary sarcoidosis in USA (NCT01732211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top